The estimated Net Worth of Tracy Zimmermann is at least 631 千$ dollars as of 29 January 2024. Dr Zimmermann owns over 5,021 units of Generation Bio Co stock worth over 123,562$ and over the last 4 years he sold GBIO stock worth over 0$. In addition, he makes 507,921$ as Chief Devel. Officer at Generation Bio Co.
Sign up
Dr D GBIO stock SEC Form 4 insiders trading
Dr has made over 14 trades of the Generation Bio Co stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 5,021 units of GBIO stock worth 12,251$ on 29 January 2024.
The largest trade he's ever made was exercising 14,876 units of Generation Bio Co stock on 15 July 2022 worth over 36,297$. On average, Dr trades about 5,101 units every 65 days since 2020. As of 29 January 2024 he still owns at least 50,640 units of Generation Bio Co stock.
You can see the complete history of Dr Zimmermann stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Tracy Zimmermann Ph.D. biography
Dr. Tracy Zimmermann Ph.D. is the Chief Devel. Officer at Generation Bio Co.
What is the salary of Dr D?
As the Chief Devel. Officer of Generation Bio Co, the total compensation of Dr D at Generation Bio Co is 507,921$. There are 1 executives at Generation Bio Co getting paid more, with Dr. Cameron Geoffrey McDonough having the highest compensation of 856,885$.
How old is Dr D?
Dr D is 51, he's been the Chief Devel. Officer of Generation Bio Co since . There are 2 older and 2 younger executives at Generation Bio Co. The oldest executive at Generation Bio Co. is Dr. Robert Kotin Ph.D., 65, who is the Co-Founder & Advisor.
What's Dr D's mailing address?
Tracy's mailing address filed with the SEC is C/O GENERATION BIO CO., 301 BINNEY ST, , CAMBRIDGE, MA, 02142.
Insiders trading at Generation Bio Co
Over the last 4 years, insiders at Generation Bio Co have traded over 37,722,950$ worth of Generation Bio Co stock and bought 4,282,125 units worth 70,408,633$ . The most active insiders traders include Jason P Rhodes、Biomedical Innovation Maste...、Public Equities, L.P.Minne .... On average, Generation Bio Co executives and independent directors trade stock every 11 days with the average trade being worth of 116,471$. The most recent stock trade was executed by Yalonda Howze on 15 July 2024, trading 3,347 units of GBIO stock currently worth 8,167$.
What does Generation Bio Co do?
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
What does Generation Bio Co's logo look like?
Complete history of Dr Zimmermann stock trades at Generation Bio Co
Generation Bio Co executives and stock owners
Generation Bio Co executives and other stock owners filed with the SEC include:
-
Dr. Cameron Geoffrey McDonough,
Pres, CEO, Sec. & Director -
Dr. Tracy Zimmermann Ph.D.,
Chief Devel. Officer -
Dr. Matthew Norkunas M.B.A., M.D.,
Chief Financial Officer -
Antoinette Paone M.B.A., M.S.,
Sr. VP & Head of Regulatory Affairs and Quality -
Dr. Douglas Kerr M.B.A., M.D., Ph.D.,
Chief Medical Officer -
Sara Den Besten,
Chief People Officer -
Phillip Samayoa Ph.D.,
Sr. VP & Head of Corp. Devel. -
Dr. Jennifer Elliott Esq., J.D., Ph.D.,
Chief Legal Officer -
Dr. Matthew Stanton Ph.D.,
Chief Scientific Officer -
Dr. Robert Kotin Ph.D.,
Co-Founder & Advisor -
Ronald Harold Wilfred Cooper,
-
Venture Fund X, L.P.Atlas V...,
-
Capital, Llc Casdin Eli Casdin,
-
Biomedical Innovation Maste...,
10% owner -
Public Equities, L.P.Minne ...,
-
Venture Fund X, L.P. Atlas,
10% owner -
Gustav Christensen,
-
Jeffrey M Jonas,
-
James E Deerfield Mgmt L.P....,
-
Dannielle Appelhans,
-
Venture Fund X, L.P.Atlas V...,
-
Matthew Norkunas,
CHIEF FINANCIAL OFFICER -
Mark D. Angelino,
CHIEF OPERATING OFFICER -
Matthew Stanton,
CHIEF SCIENTIFIC OFFICER -
Geoff Mcdonough,
PRESIDENT AND CEO -
Tracy Zimmermann,
CHIEF DEVELOPMENT OFFICER -
Donald William Nicholson,
-
Charles A Jr Rowland,
-
Douglas Kerr,
CHIEF MEDICAL OFFICER -
Venture Associates X, L.P.A...,
-
Venture Associates X, L.P.A...,
-
Anthony G. Quinn,
-
Venture Associates X, L.P.A...,
-
Jason P Rhodes,
-
Catherine Stehman Breen,
-
Antoinette Paone,
CHIEF OPERATING OFFICER -
Phillip Samayoa,
CHIEF STRATEGY OFFICER -
Yalonda Howze,
CHIEF LEGAL OFFICER